Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use

Cytokine and Growth Factor Reviews

Volumn 26, Issue 2, 2015, Pages 121-131

  Antonelli, Guido ^a   Scagnolari, Carolina ^a   Moschella, Federica ^b   Proietti, Enrico ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Cancer; Interferon; Interferon therapy; Resistance to interferon therapy; Viral infection

Indexed keywords

ALBINTERFERON ALPHA2B; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHAN1 INTERFERON; CONSENSUS INTERFERON; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; RECOMBINANT PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG RESPONSE; HAIRY CELL LEUKEMIA; HEMATOLOGIC MALIGNANCY; HEPATITIS C; HOST; HUMAN; IMMUNOMODULATION; KIDNEY CARCINOMA; MELANOMA; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS LOAD; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; IMMUNOLOGY; INNATE IMMUNITY; NEOPLASMS;

HEPATITIS C VIRUS;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNITY, INNATE; INTERFERON TYPE I; INTERFERON-ALPHA; NEOPLASMS; RECOMBINANT PROTEINS;

EID: 84926513317     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.12.006     Document Type: Article

References (142)

1. Pieters T. Interferon: the science and selling of a miracle drug 2005, Routledge, London and New York.
2. Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957, 147:258-267.
3. Gresser I. Production of interferon by suspensions of human leucocytes. Proc Soc Exp Biol Med 1961, 108:799-803.
4. Strander H., Cantell K. Production of interferon by human leukocytes in vitro. Ann Med Exp Biol Fenn 1966, 44:265-273.
5. Strander H., Adamson U., Aparisi T., Brostrom L.A., Cantell K., Einhorn S., et al. Adjuvant interferon treatment of human osteosarcoma. Recent Results Cancer Res 1978, 68:40-44.
6. Gresser I., Bourali C., Levy J.P., Fontaine-Brouty-Boye D., Thomas M.T. Increased survival in mice inoculated with tumor cells and treated with interferon preparations. Proc Natl Acad Sci U S A 1969, 63:51-57.
7. Strander H. The action of interferons on virus-associated human neoplasms. Cancer Surv 1989, 8:755-792.
8. Ho M. Editorial: interferon and hepatitis B virus. N Engl J Med 1976, 295:562-563.
9. Greenberg H.B., Pollard R.B., Lutwick L.I., Gregory P.B., Robinson W.S., Merigan T.C. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976, 295:517-522.
10. Taniguchi T., Saka M., Fujii-Kuriyama Y., Muramatsu M., Kobayashi M., Sudo T. Construction and identification of a bacterial plasmid containing the human fibroblast interferon gene sequence. Proc Jpn Acad 1979, 55B:464-469.
11. Nagata S., Taira H., Hall A., Johnsrud L., Streuli M., Ecsodi J., et al. Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature 1980, 284:316-320.
12. Gray P.W., Goeddel D.V. Structure of the human immune interferon gene. Nature 1982, 298:859-863.
13. Staehelin T., Hobbs D.S., Kung H., Lai C.Y., Pestka S. Purification and characterization of recombinant human leukocyte interferon (IFLrA) with monoclonal antibodies. J Biol Chem 1981, 256:9750-9754.
14. Hitzeman R.A., Leung D.W., Perry L.J., Kohr W.J., Levine H.L., Goeddel D.V. Secretion of human interferons by yeast. Science 1983, 219:620-625.
15. Derynck R., Content J., DeClercq E., Volckaert G., Tavernier J., Devos R., et al. Isolation and structure of a human fibroblast interferon gene. Nature 1980, 285:542-547.
16. Goeddel D.V., Shepard H.M., Yelverton E., Leung D., Crea R., Sloma A., et al. Synthesis of human fibroblast interferon by E. coli. Nucleic Acids Res 1980, 8:4057-4074.
17. Marcellin P., Lau G.K., Bonino F., Farci P., Hadziyannis S., Jin R., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351:1206-1217.
18. Scagnolari C., Antonelli G. Antiviral activity of the interferon alpha family: biological and pharmacological aspects of the treatment of chronic hepatitis C. Expert Opin Biol Ther 2013, 13:693-711.
19. Scagnolari C., Trombetti S., Solda A., Selvaggi C., Monteleone K., Spano L., et al. Pandemic 2009 H1N1 influenza virus is resistant to the antiviral activity of several interferon alpha subtypes. J Interferon Cytokine Res 2011, 31:475-479.
20. Scagnolari C., Trombetti S., Selvaggi C., Carbone T., Monteleone K., Spano L., et al. In vitro sensitivity of human metapneumovirus to type I interferons. Viral Immunol 2011, 24:159-164.
21. Gibbert K., Schlaak J.F., Yang D., Dittmer U. IFN-alpha subtypes: distinct biological activities in anti-viral therapy. Br J Pharmacol 2013, 168:1048-1058.
22. Maevis V., Mey U., Schmidt-Wolf G., Schmidt-Wolf I.G. Hairy cell leukemia: short review, today's recommendations and outlook. Blood Cancer J 2014, 4:e184.
23. Mandelli F., Avvisati G., Amadori S., Boccadoro M., Gernone A., Lauta V.M., et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990, 322:1430-1434.
24. Baldo P., Rupolo M., Compagnoni A., Lazzarini R., Bearz A., Cannizzaro R., et al. Interferon-alpha for maintenance of follicular lymphoma. Cochrane Database Syst Rev 2010, CD004629.
25. Vose J.M. Mantle cell lymphoma: 2013 update on diagnosis, risk-stratification, and clinical management. Am J Hematol 2013, 88:1082-1088.
26. Regnier-Rosencher E., Guillot B., Dupin N. Treatments for classic Kaposi sarcoma: a systematic review of the literature. J Am Acad Dermatol 2013, 68:313-331.
27. Humme D., Nast A., Erdmann R., Vandersee S., Beyer M. Systematic review of combination therapies for mycosis fungoides. Cancer Treat Rev 2014, 40:927-933.
28. Di Pucchio T., Pilla L., Capone I., Ferrantini M., Montefiore E., Urbani F., et al. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res 2006, 66:4943-4951.
29. Mitchell M.S., Abrams J., Thompson J.A., Kashani-Sabet M., DeConti R.C., Hwu W.J., et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol 2007, 25:2078-2085.
30. Fidler I.J. Regulation of neoplastic angiogenesis. J Natl Cancer Inst Monogr 2001, 10-14.
31. Rizza P., Moretti F., Belardelli F. Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity 2010, 43:204-209.
32. Rossi G.B., Albertini R., Battistini A., Coccia E.M., Romeo G., Fiorucci G., et al. Interferons and the differentiation of friend cells. Ann N Y Acad Sci 1989, 567:253-258.
33. Kotredes K.P., Gamero A.M. Interferons as inducers of apoptosis in malignant cells. J Interferon Cytokine Res 2013, 33:162-170.
34. Borden E.C., Sen G.C., Uze G., Silverman R.H., Ransohoff R.M., Foster G.R., et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007, 6:975-990.
35. Hoofnagle J.H., Mullen K.D., Jones D.B., Rustgi V., Di Bisceglie A., Peters M., et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986, 315:1575-1578.
36. Baugh J.M., Garcia-Rivera J.A., Gallay P.A. Host-targeting agents in the treatment of hepatitis C: a beginning and an end. Antiviral Res 2013, 100:555-561.
37. Janssen H.L., Reesink H.W., Lawitz E.J., Zeuzem S., Rodriguez-Torres M., Patel K., et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013, 368:1685-1694.
38. Goulet M.L., Olagnier D., Xu Z., Paz S., Belgnaoui S.M., Lafferty E.I., et al. Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity. PLoS Pathog 2013, 9:e1003298.
39. Cinatl J., Morgenstern B., Bauer G., Chandra P., Rabenau H., Doerr H.W. Treatment of SARS with human interferons. Lancet 2003, 362:293-294.
40. Scagnolari C., Vicenzi E., Bellomi F., Stillitano M.G., Pinna D., Poli G., et al. Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther 2004, 9:1003-1011.
41. Osterlund P., Pirhonen J., Ikonen N., Ronkko E., Strengell M., Makela S.M., et al. Pandemic H1N1 2009 influenza A virus induces weak cytokine responses in human macrophages and dendritic cells and is highly sensitive to the antiviral actions of interferons. J Virol 2010, 84:1414-1422.
42. Ngunjiri J.M., Mohni K.N., Sekellick M.J., Schultz-Cherry S., Webster R.G., Marcus P.I. Lethal H5N1 influenza viruses are not resistant to interferon action in human, simian, porcine or chicken cells. Nat Med 2012, 18:1456-1457.
43. Falzarano D., de Wit E., Rasmussen A.L., Feldmann F., Okumura A., Scott D.P., et al. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013, 19:1313-1317.
44. Omrani A.S., Saad M.M., Baig K., Bahloul A., Abdul-Matin M., Alaidaroos A.Y., et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis 2014.
45. Ivashkiv L.B., Donlin L.T. Regulation of type I interferon responses. Nat Rev Immunol 2014, 14:36-49.
46. de Weerd N.A., Nguyen T. The interferons and their receptors - distribution and regulation. Immunol Cell Biol 2012, 90:483-491.
47. Marijanovic Z., Ragimbeau J., Kumar K.G., Fuchs S.Y., Pellegrini S. TYK2 activity promotes ligand-induced IFNAR1 proteolysis. Biochem J 2006, 397:31-38.
48. Larner A.C., Chaudhuri A., Darnell J.E. Transcriptional induction by interferon. New protein(s) determine the extent and length of the induction. J Biol Chem 1986, 261:453-459.
49. Sarasin-Filipowicz M., Wang X., Yan M., Duong F.H., Poli V., Hilton D.J., et al. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol 2009, 29:4841-4851.
50. Fenner J.E., Starr R., Cornish A.L., Zhang J.G., Metcalf D., Schreiber R.D., et al. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat Immunol 2006, 7:33-39.
51. Malakhova O.A., Kim K.I., Luo J.K., Zou W., Kumar K.G., Fuchs S.Y., et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J 2006, 25:2358-2367.
52. Dill M.T., Makowska Z., Trincucci G., Gruber A.J., Vogt J.E., Filipowicz M., et al. Pegylated IFN-alpha regulates hepatic gene expression through transient Jak/STAT activation. J Clin Invest 2014, 124:1568-1581.
53. Chen L., Borozan I., Feld J., Sun J., Tannis L.L., Coltescu C., et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005, 128:1437-1444.
54. Randall G., Chen L., Panis M., Fischer A.K., Lindenbach B.D., Sun J., et al. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 2006, 131:1584-1591.
55. Guo Y., Chinyengetere F., Dolinko A.V., Lopez-Aguiar A., Lu Y., Galimberti F., et al. Evidence for the ubiquitin protease UBP43 as an antineoplastic target. Mol Cancer Ther 2012, 11:1968-1977.
56. Gracias D.T., Stelekati E., Hope J.L., Boesteanu A.C., Doering T.A., Norton J., et al. The microRNA miR-155 controls CD8(+) T cell responses by regulating interferon signaling. Nat Immunol 2013, 14:593-602.
57. Xu G., Yang F., Ding C.L., Wang J., Zhao P., Wang W., et al. MiR-221 accentuates IFNs anti-HCV effect by downregulating SOCS1 and SOCS3. Virology 2014, 462-463:343-350.
58. Ji J., Shi J., Budhu A., Yu Z., Forgues M., Roessler S., et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009, 361:1437-1447.
59. Pawlotsky J.M. Treatment of hepatitis C: how will we use viral kinetics, response-guided therapy?. Curr Gastroenterol Rep 2013, 15:309.
60. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995, 96:224-230.
61. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996, 334:77-81.
62. Kurosaki M., Enomoto N., Murakami T., Sakuma I., Asahina Y., Yamamoto C., et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology 1997, 25:750-753.
63. Komatsu H., Fujisawa T., Inui A., Miyagawa Y., Onoue M. Mutations in the nonstructural protein 5A gene and response to interferon therapy in young patients with chronic hepatitis C virus 1b infection. J Med Virol 1997, 53:361-365.
64. Hofmann W.P., Zeuzem S., Sarrazin C. Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy. J Clin Virol 2005, 32:86-91.
65. Berg T., Mas Marques A., Hohne M., Wiedenmann B., Hopf U., Schreier E. Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment. Hepatology 2000, 32:1386-1395.
66. Macquillan G.C., Niu X., Speers D., English S., Garas G., Harnett G.B., et al. Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population. J Gastroenterol Hepatol 2004, 19:551-557.
67. Munoz de Rueda P., Casado J., Paton R., Quintero D., Palacios A., Gila A., et al. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses. J Virol 2008, 82:6644-6653.
68. Gerotto M., Dal Pero F., Pontisso P., Noventa F., Gatta A., Alberti A. Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon. Gastroenterology 2000, 119:1649-1655.
69. Maekawa S., Enomoto N. Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. J Gastroenterol 2009, 44:1009-1015.
70. El-Shamy A., Shoji I., El-Akel W., Bilasy S.E., Deng L., El-Raziky M., et al. NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients. J Clin Microbiol 2012, 50:3886-3892.
71. Bellecave P., Sarasin-Filipowicz M., Donze O., Kennel A., Gouttenoire J., Meylan E., et al. Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. Hepatology 2010, 51:1127-1136.
72. Akuta N., Suzuki F., Hirakawa M., Kawamura Y., Yatsuji H., Sezaki H., et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010, 52:421-429.
73. Maekawa S., Sakamoto M., Miura M., Kadokura M., Sueki R., Komase K., et al. Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection. Hepatology 2012, 56:1611-1621.
74. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
75. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
76. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41:1100-1104.
77. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41:1105-1109.
78. Antonelli G., Simeoni E., Turriziani O., Tesoro R., Redaelli A., Roffi L., et al. Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy. J Interferon Cytokine Res 1999, 19:243-251.
79. Ji X., Cheung R., Cooper S., Li Q., Greenberg H.B., He X.S. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology 2003, 37:610-621.
80. Heim M.H. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol 2013, 13:535-542.
81. Giannelli G., Guadagnino G., Dentico P., Antonelli G., Antonaci S. MxA and PKR expression in chronic hepatitis C. J Interferon Cytokine Res 2004, 24:659-663.
82. Bellecave P., Moradpour D. A fresh look at interferon-alpha signaling and treatment outcomes in chronic hepatitis C. Hepatology 2008, 48:1330-1333.
83. Sarasin-Filipowicz M., Oakeley E.J., Duong F.H., Christen V., Terracciano L., Filipowicz W., et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008, 105:7034-7039.
84. Scagnolari C., Bellomi F., Trombetti S., Casato M., Carlesimo M., Bagnato F., et al. Expression of biomarkers of interferon type I in patients suffering from chronic diseases. Clin Exp Immunol 2007, 147:270-276.
85. Dill M.T., Makowska Z., Duong F.H., Merkofer F., Filipowicz M., Baumert T.F., et al. Interferon-gamma-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology 2012, 143:777-786. e1-6.
86. Jouan L., Chatel-Chaix L., Melancon P., Rodrigue-Gervais I.G., Raymond V.A., Selliah S., et al. Targeted impairment of innate antiviral responses in the liver of chronic hepatitis C patients. J Hepatol 2012, 56:70-77.
87. Lau D.T., Negash A., Chen J., Crochet N., Sinha M., Zhang Y., et al. Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology 2013, 144:402-413. e12.
88. Bolen C.R., Ding S., Robek M.D., Kleinstein S.H. Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology 2014, 59:1262-1272.
89. Olagnier D., Hiscott J. Type I and type III interferon-induced immune response: it's a matter of kinetics and magnitude. Hepatology 2014, 59:1225-1228.
90. de Weerd N.A., Vivian J.P., Nguyen T.K., Mangan N.E., Gould J.A., Braniff S.J., et al. Structural basis of a unique interferon-beta signaling axis mediated via the receptor IFNAR1. Nat Immunol 2013, 14:901-907.
91. Prokunina-Olsson L., Muchmore B., Tang W., Pfeiffer R.M., Park H., Dickensheets H., et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013, 45:164-171.
92. Riva E., Scagnolari C., Turriziani O., Antonelli G. Hepatitis C virus and interferon type III (interferon lambda 3/interleukin 28B and interferon lambda 4): genetic basis of susceptibility to infection and response to antiviral treatment. Clin Microbiol Infect 2014.
93. Amanzada A., Kopp W., Spengler U., Ramadori G., Mihm S. Interferon-lambda4 (IFNL4) transcript expression in human liver tissue samples. PLOS ONE 2013, 8:e84026.
94. Meissner E.G., Wu D., Osinusi A., Bon D., Virtaneva K., Sturdevant D., et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 2014, 124:3352-3363.
95. Thomas E., Feld J.J., Li Q., Hu Z., Fried M.W., Liang T.J. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2011, 53:32-41.
96. Tokumoto Y., Hiasa Y., Uesugi K., Watanabe T., Mashiba T., Abe M., et al. Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8. J Infect Dis 2012, 205:1121-1130.
97. Gresser I., Tovey M.G. Antitumor effects of interferon. Biochim Biophys Acta 1978, 516:231-247.
98. Belardelli F., Gresser I., Maury C., Maunoury M.T. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. II. Role of host mechanisms. Int J Cancer 1982, 30:821-825.
99. Belardelli F., Ferrantini M., Proietti E., Kirkwood J.M. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002, 13:119-134.
100. Moschella F., Proietti E., Capone I., Belardelli F. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Ann N Y Acad Sci 2010, 1194:169-178.
101. Nissen M.H., Plesner T., Larsen J.K., Olesen B.K., Ernst P. Enhanced expression in vivo of HLA-ABC antigens and beta 2-microglobulin on human lymphoid cells induced by human interferon-alpha in patients with lung cancer. Enhanced expression of class I major histocompatibility antigens prior to treatment. Clin Exp Immunol 1985, 59:327-335.
102. Webb D.S., Gerrard T.L. IFN-alpha and IFN-gamma can affect both monocytes and tumor cells to modulate monocyte-mediated cytotoxicity. J Immunol 1990, 144:3643-3648.
103. Trinchieri G., Santoli D. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med 1978, 147:1314-1333.
104. Tough D.F., Borrow P., Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996, 272:1947-1950.
105. Paquette R.L., Hsu N.C., Kiertscher S.M., Park A.N., Tran L., Roth M.D., et al. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol 1998, 64:358-367.
106. Santini S.M., Lapenta C., Logozzi M., Parlato S., Spada M., Di Pucchio T., et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 2000, 191:1777-1788.
107. Moschella F., Bisikirska B., Maffei A., Papadopoulos K.P., Skerrett D., Liu Z., et al. Gene expression profiling and functional activity of human dendritic cells induced with IFN-alpha-2b: implications for cancer immunotherapy. Clin Cancer Res 2003, 9:2022-2031.
108. Brinkmann V., Geiger T., Alkan S., Heusser C.H. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J Exp Med 1993, 178:1655-1663.
109. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., Tough D.F. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001, 14:461-470.
110. Pace L., Vitale S., Dettori B., Palombi C., La Sorsa V., Belardelli F., et al. APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions. J Immunol 2010, 184:5969-5979.
111. Bacher N., Raker V., Hofmann C., Graulich E., Schwenk M., Baumgrass R., et al. Interferon-alpha suppresses cAMP to disarm human regulatory T cells. Cancer Res 2013, 73:5647-5656.
112. Bracci L., Canini I., Venditti M., Spada M., Puzelli S., Donatelli I., et al. Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus. Vaccine 2006, 24(Suppl. 2):56-57.
113. Sistigu A., Yamazaki T., Vacchelli E., Chaba K., Enot D.P., Adam J., et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014, 20:1301-1309.
114. Gogas H., Ioannovich J., Dafni U., Stavropoulou-Giokas C., Frangia K., Tsoutsos D., et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006, 354:709-718.
115. Naveau S., Emilie D., Borotto E., Portier A., Lazizi Y., Giraud V., et al. Interleukin-1 receptor antagonist plasma concentration is specifically increased by alpha-2A-interferon treatment. J Hepatol 1997, 27:272-275.
116. Cotler S.J., Craft T., Ferris M., Morrisey M., McCone J., Reddy K.R., et al. Induction of IL-1Ra in resistant and responsive hepatitis C patients following treatment with IFN-con1. J Interferon Cytokine Res 2002, 22:549-554.
117. Malone D.F., Falconer K., Weiland O., Sandberg J.K. The dynamic relationship between innate immune biomarkers and interferon-based treatment effects and outcome in hepatitis C virus infection is altered by telaprevir. PLOS ONE 2014, 9:e105665.
118. Ippolito G., Capobianchi M.R., Lanini S., Antonelli G. Is hepatitis C virus eradication around the corner only 25 years after its discovery?. Int J Antimicrob Agents 2014.
119. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18:767-811.
120. Lee C.K., Rao D.T., Gertner R., Gimeno R., Frey A.B., Levy D.E. Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol 2000, 165:3571-3577.
121. Banchereau J., Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006, 25:383-392.
122. Garcin G., Paul F., Staufenbiel M., Bordat Y., Van der Heyden J., Wilmes S., et al. High efficiency cell-specific targeting of cytokine activity. Nat Commun 2014, 5:3016.
123. Trinchieri G. Type I interferon: friend or foe?. J Exp Med 2010, 207:2053-2063.
124. Bosinger S.E., Sodora D.L., Silvestri G. Generalized immune activation and innate immune responses in simian immunodeficiency virus infection. Curr Opin HIV AIDS 2011, 6:411-418.
125. Hughes R., Towers G., Noursadeghi M. Innate immune interferon responses to human immunodeficiency virus-1 infection. Rev Med Virol 2012, 22:257-266.
126. Teijaro J.R., Ng C., Lee A.M., Sullivan B.M., Sheehan K.C., Welch M., et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013, 340:207-211.
127. Wilson E.B., Yamada D.H., Elsaesser H., Herskovitz J., Deng J., Cheng G., et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013, 340:202-207.
128. Sandler N.G., Bosinger S.E., Estes J.D., Zhu R.T., Tharp G.K., Boritz E., et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 2014, 511:601-605.
129. Quesada J.R., Reuben J., Manning J.T., Hersh E.M., Gutterman J.U. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 1984, 310:15-18.
130. Talpaz M., Kantarjian H.M., McCredie K.B., Keating M.J., Trujillo J., Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987, 69:1280-1288.
131. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., Smith T.J., Borden E.C., Blum R.H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996, 14:7-17.
132. Flanigan R.C., Salmon S.E., Blumenstein B.A., Bearman S.I., Roy V., McGrath P.C., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345:1655-1659.
133. Ho M. Interferon-like viral inhibitor in rabbits after intravenous administration of endotoxin. Science 1964, 146:1472-1474.
134. Field A.K., Tytell A.A., Lampson G.P., Hilleman M.R. Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. Proc Natl Acad Sci U S A 1967, 58:1004-1010.
135. Kerr I.M., Brown R.E., Ball L.A. Increased sensitivity of cell-free protein synthesis to double-stranded RNA after interferon treatment. Nature 1974, 250:57-59.
136. Medzhitov R., Preston-Hurlburt P., Janeway C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997, 388:394-397.
137. Der S.D., Zhou A., Williams B.R., Silverman R.H. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 1998, 95:15623-15628.
138. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413:732-738.
139. Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003, 4:69-77.
140. Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E., et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003, 4:63-68.
141. Yoneyama M., Kikuchi M., Natsukawa T., Shinobu N., Imaizumi T., Miyagishi M., et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004, 5:730-737.
142. Pedersen I.M., Cheng G., Wieland S., Volinia S., Croce C.M., Chisari F.V., et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007, 449:919-922.